Abpro Stock
Abpro is a biotechnology company focused on therapeutics, diagnostics, and research.
Sign up today and learn more about Abpro Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Abpro Stock
Abpro is a biotechnology company dedicated to accelerating biological research by providing superior tools to researchers worldwide. As a pioneer of industrial biochemistry and an emerging leader in the reagents field, they have developed a proprietary technology platform that allows for faster, more efficient production of recombinant proteins and antibodies. As a result, Abpro delivers superior quality products at industry-leading speeds. Abpro leveraging these platforms, both independently and through collaborations with global pharmaceutical companies and research institutions to develop therapeutic antibodies for use in immuno-oncology, ophthalmology, and other disease areas. The DiversImmune platform enables the generation of novel antibodies and next-generation antibody therapies.
Funding History
March 2016 | $12.4M |
---|---|
April 2017 | $10.0M |
January 2020 | $18.0M |
April 2022 | $2.0M |
Management
CEO & CO-FOUNDER
Eugene Cha
SVP OF STRATEGIC ALLIANCES
John Xu
Chairman & CEO
Ian Chan
CMO & SVP
Robert J. Markelewicz
Press
bioworld - Dec, 19 2023
Celltrion, Cyron ink $882M deal for polyspecific antibodiesfinance - Dec, 19 2023
Age-Related Macular Degeneration Market to Grow Rapidly ...news - Dec, 19 2023
Portage Fintech Acquisition Changes Name to Perception ...bizjournals - Sep, 25 2023
Antibody maker Abpro to go public via SPAC dealfiercebiotech - Sep, 23 2023
Antibody biotech Abpro taps SPAC to get back on Nasdaq track 5 years after axed IPO